Clinical trial NCT06609941: Additive Effects of Alternative Nostril Breathing with Pharmacological Management on Dyspnea and Control Pause in Patients with Bronchial Asthma
Official title: Additive Effects of Alternative Nostril Breathing with Pharmacological Management on Dyspnea and Control Pause in Patients with Bronchial Asthma
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Bronchial Asthma
Keywords: Dyspnea, asthma control, peak expiratory flow rate
Lead sponsor: Foundation University Islamabad
Sponsor class: OTHER
First posted: 2024-09-24
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: This is a randomized controlled trial having two groups. One group will receive (interventional group) alternative nostril breathing along with pharmacological management and the other group (control group) will receive only pharmacological management.
Primary purpose: TREATMENT

Brief summary: Bronchial asthma is a widespread chronic condition charactrized by inflammation and narrowing of airways, leading to repeateted episodes of breathlessness, wheezing and labored breathing.Breathing exercises help to manage hyperventilation often seen in asthmatic patients. To handle respiratory complications asthmatics are advised to practise nasal breathing techniques in conjunction with their prescribed medications.

Detailed description: Bronchial asthma is a very common chronic disease marked by inflammation and constriction of airways, resulting in recurrent episodes of breathlessness, wheezing and decrease work of breathing. Breathing exercises help to manage hyperventilation associated with asthma. In order to manage respiratory conditions asthmatic patients are encouraged for nasal breathing techniques along with pharmacological management. Hence the objective of the study is to compare the effects of alternative nostril breathing along with pharmacological management versus pharmacological management alone on dyspnea, control pause, asthma control and peak expiratory flow rate in patients with bronchial asthma.

Eligibility criteria: Inclusion Criteria:

* Adults: aged (18-45 years)
* Gender: Both males and females
* Grade1- Grade 4 on Modified MRC dyspnea scale
* Asthma severity classes (intermediate, mild persistent and moderate persistent asthma) acc. to NAEPP national asthma education and prevention program guidlin

Exclusion Criteria:

* Patients having acute exacerbation of COPD or status asthmaticus
* Patients diagnosed with acute infections
* Patients unable to follow command/ instructions
* Asthma patients with \>40 sec control pause duration
* Patients who fall in red zone of asthma action plan (PEFR \< 50%)

Primary outcomes:
measure: Dyspnea
timeFrame: 4 weeks
measure: Control pause
timeFrame: 4 weeks
measure: Asthma control
timeFrame: 4 weeks
measure: Peak expiratory flow rate.
timeFrame: 4 Weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Rawalpindi
country: Pakistan
facility: Foundation University College of Physical Therapy
state: Punjab
Study officials:
References: